JAK2 V617F Mutation Quant Rslt

Laboratory assay overview

This advanced DNA-based, next-generation sequencing (NGS) assay analyses leukocytes from blood or bone marrow aspirate for mutation at condon 617 of JAK2. The JAK2 V617F mutation is associated with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Laboratory assay overview

The JAK2V617F (exon 14) mutation analysis can be used in conjunction with bone marrow histology and cytogenetic analysis to assist in the diagnosis of myeloproliferative neoplasms (MPN). The JAK2V617F mutation is found in almost all patients with polycythemia vera (PV) and in nearly one- half of those with idiopathic myelofibrosis (IMF) and with essential thrombocythemia (ET). The V617F mutation has also been detected, although infrequently, in other myeloid disorders, such as chronic myelomonocytic leukemia and chronic neutrophilic leukemia.

Laboratory assay overview

The quantitative real-time PCR assay detects V617F mutation (c.1849 G>T) observed in approximately 95% polycythemia vera (pv), 55% essential thrombocythemia (ET), and 55% primary myelofibrosis (PMF). It is also infrequently present (3% to 5%) in myelodysplastic syndrome, chronic myelomonocytic leukemia, and other atypical chronic myeloid disorders. The results should be interpreted in the context of all clinical and laboratory findings. No therapeutic action should be taken based solely on these results.

Laboratory assay overview

Molecular testing of blood or bone marrow is useful in the evaluation of suspected myeloproliferative neoplasms (MPN). Mutations in the JAK2, MPL and CALR genes are present in virtually all MPNs and their presence help distinguish benign reactive processes from clonal neoplasms. These mutations are generally considered mutually exclusive, although concurrent clones have been reported in rare patients. The JAK2 (Janus kinase 2) gene encodes for a non-receptor protein tyrosine kinase that activates cytokine and growth factor signaling. The V617F (c.1849 G>T) mutation results in constitutive activation of JAK2 and downstream STAT5 and ERK signaling. The V617F mutation is observed in approximately 95% of polycythemia vera (PV), 60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF). It is also infrequently present (3-5%) in myelodysplastic syndrome, chronic myelomonocytic leukemia and other atypical chronic myeloid disorders. JAK2 mutation allele burden correlates with clinical phenotype, with low levels of mutant allele characterized by thrombocytosis, intermediate levels with erythrocytosis and high mutant allele burden, correlating with enhanced myelopoiesis of the BM, leukocytosis, increasing spleen size and circulating CD34-positive cells. The CALR (Calreticulin) gene encodes for a multifunctional calcium-binding protein involved in many cellular activities such as growth, proliferation, adhesion and programmed cell death. Among patients with JAK2- negative MPNs, CALR mutations are found in approximately 70% of patients with JAK2-negative essential thrombocythemia (ET) and 60-88% of patients with JAK2-negative primary myelofibrosis(PMF). Only a minority of patients (approximately 8%) with myelodysplasia have mutations in the CALR gene. CALR mutations are rarely detected in patients with de novo acute myeloid leukemia, chronic myelogenous leukemia, lymphoid leukemia or solid tumors. CALR mutations are not detected in polycythemia and generally appear to be mutually exclusive with JAK2 mutations and MPL mutations. The majority of mutational changes involve a variety of insertion or deletion mutations in exon 9 of the calreticulin gene: approximately 53% of all CALR mutations are a 52 bp deletion (type-1) while the second most prevalent mutation (approximately 32%) contains a 5 bp insertion (type-2). Other mutations (non-type 1 or type 2) are seen in a small minority of cases. CALR mutations in PMF tend to be associated with a favorable prognosis compared to JAK2V617F mutations, whereas primary myelofibrosis negative for CALR , JAK2V617F and MPL mutations (so-called triple negative) is associated with a poor prognosis and shorter survival. The MPL (myeloproliferative leukemia virus oncogene) gene encodes the thrombopoietin receptor, which regulates hematopoiesis and megakaryopoiesis. Activating MPL mutations are associated with a subset of myeloproliferative neoplasms and acute megakaryoblastic leukemia. MPL W515 mutations are present in approximately 5-8% of patients with primary myelofibrosis (PMF) and 1-4% of patients with essential thrombocythemia (ET). The S505 mutation is detected in patients with hereditary thrombocythemia.

Laboratory assay overview

Molecular testing of blood or bone marrow is useful in the evaluation of suspected myeloproliferative neoplasms (MPN). Mutations in the JAK2 , MPL and CALR genes are present in virtually all MPNs and their presence help distinguish benign reactive processes from clonal neoplasms. These mutations are generally considered mutually exclusive, although concurrent clones have been reported in rare patients. This test will assess for the JAK2V617F (exon 14) mutation first and will reflex to CALR mutation analysis, MPL mutation analysis, and JAK2 exon 12 to 15 mutation analysis if the JAK2V617F mutation is negative. The JAK2 (Janus kinase 2) gene encodes for a non-receptor protein tyrosine kinase that activates cytokine and growth factor signaling. The V617F (c.1849 G>T) mutation results in constitutive activation of JAK2 and downstream STAT5 and ERK signaling. The V617F mutation is observed in approximately 95% of polycythemia vera (PV), 60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF). It is also infrequently present (3-5%) in myelodysplastic syndrome, chronic myelomonocytic leukemia and other atypical chronic myeloid disorders. A small percentage of JAK2 mutation positive patients (3.3%) contain other non-V617F mutations within exons 12 to 15. In particular, mutations in exon 12 of JAK2 have been described in approximately 3% of patients with PV. JAK2 allele burden correlates with clinical phenotype, with low levels of mutant allele characterized by thrombocytosis, intermediate levels with erythrocytosis and high mutant allele burden, correlating with enhanced myelopoiesis of the BM, leukocytosis, increasing spleen size and circulating CD34-positive cells. The CALR (Calreticulin) gene encodes for a multifunctional calcium-binding protein involved in many cellular activities such as growth, proliferation, adhesion and programmed cell death. Among patients with JAK2- negative MPNs, CALR mutations are found in approximately 70% of patients with JAK2 -negative essential thrombocythemia (ET) and 60-88% of patients with JAK2 -negative primary myelofibrosis(PMF). Only a minority of patients (approximately 8%) with myelodysplasia have mutations in the CALR gene. CALR mutations are rarely detected in patients with de novo acute myeloid leukemia, chronic myelogenous leukemia, lymphoid leukemia or solid tumors. CALR mutations are not detected in polycythemia and generally appear to be mutually exclusive with JAK2 mutations and MPL mutations. The majority of mutational changes involve a variety of insertion deletion mutations in exon 9 of the calreticulin gene: approximately 53% of all CALR mutations are a 52 bp deletion (type-1) while the second most prevalent mutation (approximately 32%) contains a 5 bp insertion (type-2). Other mutations (non-type 1 or type 2) are seen in a small minority of cases. CALR mutations in PMF tend to be associated with a favorable prognosis compared to JAK2V617F mutations, whereas primary myelofibrosis negative for CALR, JAK2V617F and MPL mutations (so-called triple negative) is associated with a poor prognosis and shorter survival. The MPL (myeloproliferative leukemia virus oncogene) gene encodes the thrombopoietin receptor, which regulates hematopoiesis and megakaryopoiesis. Activating MPL mutations are associated with a subset of myeloproliferative neoplasms and acute megakaryoblastic leukemia. MPL W515 mutations are present in approximately 5-8% of patients with primary myelofibrosis (PMF) and 1-4% of patients with essential thrombocythemia (ET). The S505 mutation is detected in patients with hereditary thrombocythemia.

Laboratory assay overview

The MPN Core Diagnostic panel is an evidence-based, disease targeted mutational analysis panel, performed by Next-generation sequencing (NGS). Testing for disease-defining driver mutations in JAK2 V617F, JAK2 exon 12, CALR, and MPL, as part of the early evaluation for BCR-ABL1-negative myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), assists with diagnosis; is supported by medical guidelines; should be performed using highly sensitive molecular methods; and also impacts prognosis and therapy selection. The panel tests nucleic acid harvested from leukocytes from blood or bone marrow specimens. This panel does NOT include testing for the BCR-ABL1 rearrangement, which can be detected using BCR-ABL1 Gene Rearrangement, Quantitative, PCR or FISH, CML/ALL, BCR/ABL Translocation 9;22. MPN patients who are found to be pan-negative (~10% of cases) on the MPN Core Diagnostic panel may be candidates for CSF3R Mutation Analysis or Quest?s LeukoVantage®, Myeloproliferative Neoplasms (MPN), which offers an expanded panel of gene targets supported by medical literature. Results of this assay should be correlated with morphology and other clinical and laboratory findings for definitive diagnosis and classification.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.